tranxene - نتائج البحث

سويسرا - الإيطالية - Swissmedic (Swiss Agency for Therapeutic Products)

baclocalm 10 mg compresse

labatec pharma sa - baclofenum - compresse - baclofenum 10 mg, excipiens pro compresso. - myotonolytique - synthetika

سويسرا - الإيطالية - Swissmedic (Swiss Agency for Therapeutic Products)

baclocalm 25 mg compresse

labatec pharma sa - baclofenum - compresse - baclofenum 25 mg, excipiens pro compresso. - myotonolytique - synthetika

سويسرا - الإيطالية - Swissmedic (Swiss Agency for Therapeutic Products)

liohem 10 mg compresse

hemony pharmaceutical switzerland gmbh - baclofenum - compresse - baclofenum 10.0 mg, tritici amylum 61.0 mg, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, povidonum k 30, pro compresso. - myotonolyticum - synthetika

سويسرا - الإيطالية - Swissmedic (Swiss Agency for Therapeutic Products)

liohem 25 mg compresse

hemony pharmaceutical switzerland gmbh - baclofenum - compresse - baclofenum 25.0 mg, tritici amylum 83.0 mg, cellulosum microcristallinum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso. - myotonolyticum - synthetika

الاتحاد الأوروبي - الإيطالية - EMA (European Medicines Agency)

rivaroxaban accord

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - agenti antitrombotici - prevenzione del tromboembolismo venoso (tev) in pazienti adulti sottoposti a chirurgia sostitutiva elettiva dell'anca o del ginocchio. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 per haemodynamically instabile pe pazienti). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 e 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. trattamento della trombosi venosa profonda (tvp) ed embolia polmonare (ep) e prevenzione della recidiva di tvp e ep nell'adulto. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.